JCI Falls 0.13% to 6,591.77
The Jakarta Composite Index (JCI), in the first trading session on Thursday (30/12), corrected 0.13% or 8,910 points to 6,591,77
JCI Seen to Move Tad Higher
The Jakarta Composite Index (JCI) on Wednesday (29/12) is predicted to move higher but is limited to the range of support level of 6,558 and resistance level of 6,653.
LEO Pharma announces FDA approval of Adbry™ (tralokinumab)
• Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022.
Ahead of Christmas, JCI Seen to Move in 6.502-6.618 Range
The Jakarta Composite Index (JCI) ahead of the Christmas holiday seems to show a limited pattern of strengthening and has the potential to be in a positive range of movement.
